Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise Holdings's total equity for the quarter that ended in May. 2026 was 円6,857 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
Pharmarise Holdings Total Equity Related Terms
Pharmarise Holdings Total Equity Historical Data
* Premium members only.
The historical data trend for Pharmarise Holdings's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings (TSE:2796) has a Total Equity of 円6,857 Mil as of May. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Pharmarise Holdings and its competitors.
Is Pharmarise Holdings' Total Equity too high?
Pharmarise Holdings' current Total Equity is 円6,857 Mil. Overall, Pharmarise Holdings has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' Total Equity compare to competitors?
Pharmarise Holdings' Total Equity of 円6,857 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Healthcare Providers & Services company?
A good Total Equity depends on the Healthcare Providers & Services industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pharmarise Holdings and its competitors. Pharmarise Holdings's current Total Equity is 円6,857 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円608.01, compared to a current price of 円491.00 — trading 19.2% below its estimated fair value. The current Total Equity is 円6,857 Mil. Pharmarise Holdings' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current Total Equity is 円6,857 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円491.00 is trading 19.2% below its estimated GF Value™ of 円608.01.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
Total Equity: 円6,857 Mil
GF Value™: 円608.01 vs. price of 円491.00 (19.2% below fair value)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
50GF Score
Get the complete analysis for TSE:2796
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
